Packham G - Search Results

1

Epigenetic modulators as therapeutic targets in prostate cancer.

Graça I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jerónimo C. Graça I, et al. Among authors: packham g. Clin Epigenetics. 2016 Sep 15;8:98. doi: 10.1186/s13148-016-0264-8. eCollection 2016. Clin Epigenetics. 2016. PMID: 27651838 Free PMC article. Review.

2

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.

Hayden A, Johnson PW, Packham G, Crabb SJ. Hayden A, et al. Among authors: packham g. Breast Cancer Res Treat. 2011 May;127(1):109-19. doi: 10.1007/s10549-010-0982-0. Epub 2010 Jun 17. Breast Cancer Res Treat. 2011. PMID: 20556507

3

Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer.

Whitton B, Okamoto H, Packham G, Crabb SJ. Whitton B, et al. Among authors: packham g. Cancer Med. 2018 Aug;7(8):3800-3811. doi: 10.1002/cam4.1594. Epub 2018 Jun 21. Cancer Med. 2018. PMID: 29926527 Free PMC article. Review.

4

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Nolan L, et al. Among authors: packham g. Br J Cancer. 2008 Sep 2;99(5):689-94. doi: 10.1038/sj.bjc.6604557. Epub 2008 Aug 19. Br J Cancer. 2008. PMID: 18728657 Free PMC article. Review.

5

Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.

Ganesan A, Nolan L, Crabb SJ, Packham G. Ganesan A, et al. Among authors: packham g. Curr Cancer Drug Targets. 2009 Dec;9(8):963-81. doi: 10.2174/156800909790192428. Curr Cancer Drug Targets. 2009. PMID: 20025605 Review.

6

BAG-1 in carcinogenesis.

Sharp A, Crabb SJ, Townsend PA, Cutress RI, Brimmell M, Wang XH, Packham G. Sharp A, et al. Among authors: packham g. Expert Rev Mol Med. 2004 Mar 22;6(7):1-15. doi: 10.1017/S1462399404007537. Expert Rev Mol Med. 2004. PMID: 15033003 Review.

7

BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells.

Crabb SJ, Hague A, Johnson PW, Packham G. Crabb SJ, et al. Among authors: packham g. Oncol Rep. 2008 Mar;19(3):689-96. Oncol Rep. 2008. PMID: 18288403

8

Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A.

Crabb SJ, Howell M, Rogers H, Ishfaq M, Yurek-George A, Carey K, Pickering BM, East P, Mitter R, Maeda S, Johnson PW, Townsend P, Shin-ya K, Yoshida M, Ganesan A, Packham G. Crabb SJ, et al. Among authors: packham g. Biochem Pharmacol. 2008 Aug 15;76(4):463-75. doi: 10.1016/j.bcp.2008.06.004. Epub 2008 Jun 20. Biochem Pharmacol. 2008. PMID: 18611394

9

Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions.

Sharp A, Crabb SJ, Johnson PW, Hague A, Cutress R, Townsend PA, Ganesan A, Packham G. Sharp A, et al. Among authors: packham g. J Pharmacol Exp Ther. 2009 Nov;331(2):680-9. doi: 10.1124/jpet.109.153601. Epub 2009 Aug 18. J Pharmacol Exp Ther. 2009. PMID: 19690191 Free PMC article.

10

V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer.

Whitton B, Okamoto H, Rose-Zerilli M, Packham G, Crabb SJ. Whitton B, et al. Among authors: packham g. Mol Cancer Ther. 2021 Apr;20(4):739-748. doi: 10.1158/1535-7163.MCT-20-0662. Epub 2021 Feb 9. Mol Cancer Ther. 2021. PMID: 33563753 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page